Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis

15 Nov 2014

Abstract excerpt

OBJECTIVE: Tofacitinib is an oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). The pathways affected by tofacitinib and the effects on gene expression in situ are unknown. Therefore, tofacitinib effects on synovial pathobiology were investigated. METHODS: A randomised, double-blind, phase II serial synovial biopsy study (A3921073; NCT00976599) in patients with RA with an inadequate...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Autoimmune and Inflammatory Disorders Research
Share to Rheumatoid Arthritis Research and Therapies
Share to Spondyloarthritis Studies and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 25398374
DOI: 10.1136/annrheumdis-2014-206028

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritisPMID 25398374Read ↗

Synovial fibroblast niche shapes the efficacy–safety dynamics of JAK inhibition in rheumatoid arthritisSemantic proximity Read ↗

Janus kinase inhibitors: A therapeutic strategy for cancer and autoimmune diseasesSemantic proximity Read ↗

A review of JAK–STAT signalling in the pathogenesis of spondyloarthritis and the role of JAK inhibitionSemantic proximity Read ↗

The Use of Janus Kinase Inhibitors in Axial Spondyloarthritis: Current InsightsSemantic proximity Read ↗

JAK/STAT Inhibition Reprograms T Cell Activation and Metabolism in Inflammatory Arthritis PatientsSemantic proximity Read ↗

Upadacitinib: Mechanism of action, clinical, and translational scienceSemantic proximity Read ↗

JAK signaling was involved in the pathogenesis of Polymyalgia RheumaticaSemantic proximity Read ↗

Janus kinase inhibitors for the treatment of rheumatoid arthritis demonstrate similar profiles of in vitro cytokine receptor inhibitionSemantic proximity Read ↗

Circulating exo-miRNA-27a-5p is a novel biomarker of the tofacitinib treatment response in rheumatoid arthritisSemantic proximity Read ↗

The JAK1/3 inhibitor tofacitinib regulates Th cell profiles and humoral immune responses in myasthenia gravisSemantic proximity Read ↗

Role of Interleukin-6 in Rheumatoid Arthritis-Associated Interstitial Lung Disease: Focus on the JAK/STAT Pathway and Macrophage PolarizationSemantic proximity Read ↗

Vascular synovial phenotype indicates poor response to JAK inhibitors in rheumatoid arthritis patients: a pilot study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.